Klotho Neurosciences Faces Delisting Concerns
Ticker: GRMLW · Form: 8-K · Filed: Sep 25, 2025 · CIK: 1907223
Sentiment: bearish
Topics: delisting, compliance, regulatory
TL;DR
Klotho Neurosciences might get delisted, big trouble for shareholders.
AI Summary
Klotho Neurosciences, Inc. filed an 8-K on September 25, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of September 19, 2025. The company, formerly known as ANEW Medical, Inc. and Redwoods Acquisition Corp., is based in Omaha, NE.
Why It Matters
This filing indicates potential issues with Klotho Neurosciences' continued listing on an exchange, which could impact its stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to investors.
Key Numbers
- 001-41340 — Commission File Number (Identifies the company's SEC filing history.)
- 86-2727441 — IRS Employer Identification No (Company's tax identification number.)
Key Players & Entities
- Klotho Neurosciences, Inc. (company) — Registrant
- September 19, 2025 (date) — Date of earliest event reported
- September 25, 2025 (date) — Filing date
- ANEW Medical, Inc. (company) — Former company name
- Redwoods Acquisition Corp. (company) — Former company name
- Omaha, NE (location) — Company address
FAQ
What specific rule or standard has Klotho Neurosciences failed to satisfy?
The filing states a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard' but does not specify the exact rule in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated September 19, 2025.
What is the company's current address?
The company's business and mail address is 13576 Walnut Street, Suite A, Omaha, NE 68144.
What were Klotho Neurosciences' previous company names?
The company was formerly known as ANEW Medical, Inc. and Redwoods Acquisition Corp.
What is the SIC code for Klotho Neurosciences?
The Standard Industrial Classification code is 2836, for Biological Products (No Diagnostic Substances).
Filing Stats: 511 words · 2 min read · ~2 pages · Grade level 12.9 · Accepted 2025-09-25 16:15:44
Key Financial Figures
- $1 — tock to maintain a minimum bid price of $1 per share for 30 consecutive business d
Filing Documents
- ea0258693-8k_klotho.htm (8-K) — 27KB
- 0001213900-25-091652.txt ( ) — 244KB
- klto-20250919.xsd (EX-101.SCH) — 3KB
- klto-20250919_def.xml (EX-101.DEF) — 27KB
- klto-20250919_lab.xml (EX-101.LAB) — 37KB
- klto-20250919_pre.xml (EX-101.PRE) — 26KB
- ea0258693-8k_klotho_htm.xml (XML) — 7KB
01. Notice of Delisting or Failure to Satisfy a Continued
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 19, 2025, Klotho Neurosciences, Inc. (the "Company") received a delinquency notification letter (the "Notice") from the Nasdaq Stock Market LLC ("Nasdaq") due to the failure of the Company's common stock to maintain a minimum bid price of $1 per share for 30 consecutive business days as required by Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until March 18, 2026, to regain compliance. To regain compliance, prior to March 18, 2026, the closing bid price of the Company's common stock must be at least $1 for a minimum of ten consecutive business days. If the Company fails to timely regain compliance with Nasdaq Listing Rules, the Company's common stock will be subject to delisting from Nasdaq. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 24, 2025 KLOTHO NEUROSCIENCES, INC. By: /s/ Joseph Sinkule Name: Joseph Sinkule Title: Chief Executive Officer 2